| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| CD109 | Cynomolgus CD109 / CPAMD7 Protein, His Tag |  Cynomolgus | HEK293 |  | SDS-PAGE | $270.00 100ug |   | ||
| CD109 | Human CD109 / CPAMD7 protein, Fc Tag |  Human | HEK293 |  | SDS-PAGE | $270.00 100ug | | ||
| CD109 | Human CD109 / CPAMD7 Protein, His Tag | Human | HEK293 |  | SDS-PAGE | $270.00 100ug | | ||
| CD109 | Avitag CD9-H82E4 | Biotinylated Human CD109 / CPAMD7 Protein, His,Avitag™ (MALS & SPR verified) | Human | HEK293 |  | MALSSDS-PAGE | $360.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Clofarabine (Boyen) | BY-101 | Phase 3 Clinical | Boyen Therapeutics Inc | Leukemia, Myeloid, Acute | Details |
| Alkasar-18 | NOAC; Alkasar-18; N4-octadecyl-ara-C | Phase 1 Clinical | University of Zurich | Cerebral Hemorrhage; Neoplasms; Atrial Fibrillation | Details |
| Sapacitabine | CS-682; CYC-682 | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Leukemia; Myelodysplastic Syndromes; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Carcinoma, Non-Small-Cell Lung | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Clofarabine | CAFdA; JC0707; GZ-393590; SAR-393590; 2-Cl-2-F-araA | Approved | Genzyme Corp | Clolar, Evoltra, Ivozall, Clofarex | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Genzyme Corp | 2004-12-28 | Neoplasms; Angioimmunoblastic T-cell Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Histiocytosis, Langerhans-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Lymphoid; Intestinal Neoplasms; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Hematologic Neoplasms; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic; Solid tumours | Details |
| Nelarabine | 506U; 506-U78; GW-506U; GW-506U78; GI-262250X; NSC-686673 | Approved | Novartis Pharma Ag, Glaxosmithkline Plc | Arranon, ArranonG, Atriance | United States | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Sandoz | 2005-10-28 | Sezary Syndrome; Mycosis Fungoides; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Angioimmunoblastic T-cell Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Leukemia-Lymphoma, Adult T-Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Plasmacytoma; Lymphoma, B-Cell, Marginal Zone | Details |
